Ibogaine and Cariprazine

Major risk. D2/D3 partial-agonist antipsychotic whose ACTIVE METABOLITES have a half-life measured in weeks, so a hold of a few days leaves the drug fully on board and a recent stop date is not evidence of clearance. CYP3A4 substrate. Additive sedation. Do not stop abruptly — antipsychotic discontinuation has its own risks and a short hold would not clear it regardless. Review with the prescribing psychiatrist well before arrival, and treat a recent discontinuation as still-present drug.

Continue as prescribed — cleared by a measured lab value, not a waiting period. This medication is not stopped for treatment, and should not be stopped on our initiative — the condition it treats usually outranks the interaction. What it changes is monitoring: serum potassium and magnesium are measured before the flood dose and corrected to target, and the dose is deferred until those numbers are right rather than until a number of days have passed. Any change to the prescription belongs to the prescribing physician.

Central nervous system depression. Sedatives — benzodiazepines, gabapentinoids, alcohol, sedating antihistamines, sleep aids — add to ibogaine's own sedation, ataxia, and respiratory effects. Concomitant CNS depressants are tapered before treatment and reintroduced cautiously after the active dosing window closes.

In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Cariprazine — contact us for an individual review.